Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15991616 | 1.00 | LCK (0.39) | LCKCA1CA2GCKPI4KB | |
| SCHEMBL13437814 | 0.92 | LCK (0.39) | LCKCA1CA2PI4KB | |
| SCHEMBL24635960 | 0.91 | LCK (0.39) | LCKCA1CA2PI4KB | |
| SCHEMBL16002497 | 0.90 | CA1 (0.40) | LCKCA1CA2PI4KB | |
| SCHEMBL24635957 | 0.89 | LCK (0.37) | LCKCA1CA2PI4KB | |
| SCHEMBL13437782 | 0.83 | LCK (0.39) | LCKCA1CA2GCKPI4KB | |
| SCHEMBL5674187 | 0.83 | LCK (0.42) | LCKCA1CA2 | |
| SCHEMBL7562740 | 0.83 | LCK (0.42) | LCKCA1CA2 | |
| SCHEMBL13451827 | 0.83 | — | — | |
| SCHEMBL9691876 | 0.82 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-9630977-B2 | Cephalosporin derivatives and pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-25 | — | — | US | disclosed |
| EP-2763539-B1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-02-08 | — | — | EP | disclosed |
| EP-2763539-B1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-02-08 | — | — | EP | disclosed |
| US-9340556-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130178455-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCES, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8329684-B2 | Cephalosporin derivatives and pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-12-11 | — | — | US | disclosed |
| US-20120264727-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-10-18 | — | — | US | disclosed |
| WO-2012134184-A2 | NOVEL CEPHALOSPORIN DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 (KR) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-7696354-B2 | Cephem compounds having broad antibacterial spectrum | SHIONOGI & CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20090131655-A1 | Cephem Compounds Having Broad Antibacterial Spectrum | SHIONOGI & CO., LTD. | 2009-05-21 | — | — | US | disclosed |
| US-7384928-B2 | Broad spectrum cephem compounds | SHIONOGI & CO., LTD. (JP) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | LCK 2788/4885CA1 4714/4885CA2 2508/4885 |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, PEPD, ABCB11 | LCK 3334/4885CA1 4723/4885CA2 2491/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | LCK 2788/4885CA1 4714/4885CA2 2508/4885 |
| US-20090131655-A1 | Cephem Compounds Having Broad Antibacterial Spectrum | ZYX, NAT10, NAA50 | LCK 2536/4885CA1 4258/4885CA2 1243/4885 |
| US-20130178455-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | CSDE1, CELA1, ABCC1 | LCK 4341/4885CA1 895/4885CA2 397/4885 |
| US-20120264727-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | CSDE1, CELA1, ABCC1 | LCK 4341/4885CA1 895/4885CA2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.